{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:55:25Z","timestamp":1773867325852,"version":"3.50.1"},"reference-count":24,"publisher":"Canadian Science Publishing","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.en_GB"}],"funder":[{"name":"Canada's Drug Agency"}],"content-domain":{"domain":["cdnsciencepub.com"],"crossmark-restriction":false},"short-container-title":["Can. J. Physiol. Pharmacol."],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:p>Opioid agonist treatment (OAT) is the recommended first-line therapy for individuals with opioid use disorder. The availability of different products and prescribing guidance for OAT has rapidly evolved in recent years. Therefore, we conducted a repeated cross-sectional study using pharmacy dispensing data from six Canadian provinces to examine trends in methadone and buprenorphine use between January 2018 and December 2022. Monthly population-adjusted rates of OAT recipients were calculated by province, and annual cohorts were stratified by demographic characteristics and OAT type. Prevalence of OAT use varied across provinces, ranging from 1.03 per 1000 in Quebec to 3.59 per 1000 in British Columbia. Increases in OAT use between 2018 and 2022 were observed in Alberta (3.00\u20133.75 per 1000) and Manitoba (1.68\u20132.39 per 1000), while rates remained relatively stable elsewhere. OAT use was highest among adults aged 25\u201344 years, males, and residents of lower-income neighbourhoods. A notable shift toward buprenorphine prescribing was observed across all provinces, with 45%\u201374% of OAT recipients dispensed a buprenorphine product in 2022. These cross-provincial differences in OAT rates likely reflect variations in opioid use disorder prevalence, prescribing practices, and access to care.<\/jats:p>","DOI":"10.1139\/cjpp-2025-0171","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T21:34:36Z","timestamp":1771364076000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1139\/csp-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Opioid agonist treatment dispensing trends between 2018 and 2022 across six Canadian provinces"],"prefix":"10.1139","volume":"104","author":[{"given":"Ria","family":"Garg","sequence":"first","affiliation":[{"name":"ICES","place":["Toronto, Canada"]},{"name":"University of Toronto","place":["Toronto, Canada"]},{"name":"Li Ka Shing Knowledge Institute, St. Michael's Hospital","place":["Toronto, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bisola","family":"Hamzat","sequence":"additional","affiliation":[{"name":"Li Ka Shing Knowledge Institute, St. Michael's Hospital","place":["Toronto, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Cheung","sequence":"additional","affiliation":[{"name":"Canadian Institute for Health Information","place":["Toronto, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Eurich","sequence":"additional","affiliation":[{"name":"University of Alberta","place":["Edmonton, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Kabor\u00e9","sequence":"additional","affiliation":[{"name":"Institut National d'Excellence en Sant\u00e9 et en Services Sociaux (INESSS)","place":["Montr\u00e9al, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"de L\u00e9s\u00e9leuc","sequence":"additional","affiliation":[{"name":"Canada's Drug Agency","place":["Ottawa, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoyu","family":"Liu","sequence":"additional","affiliation":[{"name":"University of Calgary","place":["Calgary, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houssem","family":"Missaoui","sequence":"additional","affiliation":[{"name":"Institut National d'Excellence en Sant\u00e9 et en Services Sociaux (INESSS)","place":["Montr\u00e9al, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason R","family":"Randall","sequence":"additional","affiliation":[{"name":"University of Alberta","place":["Edmonton, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Shearer","sequence":"additional","affiliation":[{"name":"Li Ka Shing Knowledge Institute, St. Michael's Hospital","place":["Toronto, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Stock","sequence":"additional","affiliation":[{"name":"Canada's Drug Agency","place":["Ottawa, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Yang","sequence":"additional","affiliation":[{"name":"ICES","place":["Toronto, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1468-1965","authenticated-orcid":false,"given":"Tara","family":"Gomes","sequence":"additional","affiliation":[{"name":"ICES","place":["Toronto, Canada"]},{"name":"University of Toronto","place":["Toronto, Canada"]},{"name":"Li Ka Shing Knowledge Institute, St. Michael's Hospital","place":["Toronto, Canada"]},{"name":"University of Toronto","place":["Toronto, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"155","reference":[{"key":"refg1\/ref1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001348"},{"key":"refg2\/ref2","doi-asserted-by":"publisher","DOI":"10.24095\/hpcdp.38.6.02"},{"key":"refg3\/ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.112451"},{"key":"refg4\/ref4","volume-title":"Risk mitigation in the context of the dual public health emergencies","author":"British Columbia Centre on Substance Use","year":"2020"},{"key":"refg5\/ref5","volume-title":"A guideline for the clinical management of opioid use disorder","author":"British Columbia Centre on Substance Use","year":"2023"},{"key":"refg6\/ref6","volume-title":"Methadone treatment for people who use fentanyl: recommendations","author":"Bromley L.","year":"2021"},{"key":"refg7\/ref7","volume-title":"Opioid agonist therapy: a synthesis of Canadian guidelines for treating opioid use disorder","author":"Centre for Addiction and Mental Health","year":"2021"},{"key":"refg8\/ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-022-00323-4"},{"key":"refg9\/ref9","volume-title":"Opioid- and stimulant-related harms in Canada","author":"Federal, provincial, and territorial Special Advisory Committee on the Epidemic of Opioid Overdoses","year":"2025"},{"key":"refg10\/ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109459"},{"key":"refg11\/ref11","volume-title":"Patterns of medication and healthcare use among people who died of an opioid-related toxicity during the COVID-19 pandemic in Ontario","author":"Gomes T.","year":"2022"},{"key":"refg12\/ref12","doi-asserted-by":"publisher","DOI":"10.1111\/add.15862"},{"key":"refg13\/ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0278508"},{"key":"refg14\/ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.12865"},{"key":"refg15\/ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108651"},{"key":"refg16\/ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-14586-8"},{"key":"refg17\/ref17","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.231339"},{"key":"refg18\/ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104392"},{"key":"refg19\/ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.16954"},{"key":"refg20\/ref20","volume-title":"Modelling apparent opioid toxicity deaths during the overdose crisis","author":"Public Health Agency of Canada","year":"2024"},{"key":"refg21\/ref21","doi-asserted-by":"publisher","DOI":"10.5770\/cgj.23.420"},{"key":"refg22\/ref22","volume-title":"Postal Code Conversion File Plus (PCCF+) Version 8A1, December 2022 Postal Codes","author":"Statistics Canada","year":"2023"},{"key":"refg23\/ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-024-11281-9"},{"key":"refg24\/ref24","volume-title":"Manitoba opioid agonist therapy recommended practice manual","author":"The College of Physicians &amp; Surgeons of Manitoba Opioid Agonist Therapy Recommended Practice Working Group","year":"2023"}],"container-title":["Canadian Journal of Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdnsciencepub.com\/doi\/full-xml\/10.1139\/cjpp-2025-0171","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdnsciencepub.com\/doi\/pdf\/10.1139\/cjpp-2025-0171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:44:01Z","timestamp":1773841441000},"score":1,"resource":{"primary":{"URL":"https:\/\/cdnsciencepub.com\/doi\/10.1139\/cjpp-2025-0171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":24,"alternative-id":["10.1139\/cjpp-2025-0171"],"URL":"https:\/\/doi.org\/10.1139\/cjpp-2025-0171","relation":{},"ISSN":["0008-4212","1205-7541"],"issn-type":[{"value":"0008-4212","type":"print"},{"value":"1205-7541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"assertion":[{"value":"2026-03-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}